Suicide risk: Bipolarity is important during treatment with antidepressants [1]

British Medical Journal

Volumn 334, Issue 7589, 2007, Pages 327-

  Smith, Daniel J ^a   Walters, James T ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; MOOD STABILIZER; NEUROLEPTIC AGENT; VENLAFAXINE;

BIPOLAR DISORDER; DISEASE ASSOCIATION; DRUG USE; FAMILY HISTORY; HIGH RISK PATIENT; HUMAN; HYPOMANIA; LETTER; MAJOR DEPRESSION; MANIA; MENTAL DISEASE; MONOTHERAPY; PRIORITY JOURNAL; RISK FACTOR; SUICIDE; NOTE;

ANTIDEPRESSIVE AGENTS; BIPOLAR DISORDER; HUMANS;

EID: 33847132412     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (5)

1. Rubino A, Roskell N, Tennis P, Mines D, Weich S, Andrews E. Risk of suicide during treatment with venlafaxine, citalopram, fluoxetine, and dothiepin: retrospective cohort study. BMJ 2007;334:242-5. (3 February.)
2. Sharma V, Khan M, Smith A. A closer look at treatment resistant depression: Is it due to a bipolar diathesis? J Affect Dis 2005;84:251-7.
3. Goldberg JF, Truman CJ. Antidepressant-induced mania: an overview of current controversies. Bipolar Dis 2003;5:407-20.
4. Akiskal HS, Benazzi F, Perugi G, Rihmer Z. Agitated "unipolar" depression re-conceptualized as a depressive mixed state: implications for the antidepressant-suicide controversy. J Affect Dis 2005;85:245-58.
5. Post RM, Altshuler LL, Leverich GS, Frye MA, Nolen WA, Kupka RW, et al. Mood switch in bipolar depression: comparison of adjunctive venlafaxine, bupropion and sertraline. Br J Psychiatry 2006;189:124-31.